ArticleChemical science2016
A cooperative polymeric platform for tumor-targeted drug delivery.
Article in Chemical science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 54 citations in OpenAlex.
- Fibrinogen-Drug Nanoparticles Achieve Durable Responses in Pancreatic and Breast Cancer Murine Models.ACS pharmacology & translational science · 2026Article
- Cancer Therapy with Polymeric Nanocarriers and the Transition to Targeted Cancer Therapy: Advances and Future Directions.Pharmaceutical nanotechnology · 2026Review
- Targeted delivery and controlled release of polymeric nanomedicines for tumor therapy.Fundamental research · 2025Review
- NIR-II Light-Modulated Smart Drug Delivery System Utilizing Drug-Gated Nanocomposite Hydrogel for Boosting Anticancer Efficacy.Polymer science & technology (Washington, D.C.) · 2025Article
- Reprograming Clots for In Vivo Chemical Targeting in Traumatic Brain Injury.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Recent Advances in Poly(α-Biomolecules · 2022Review
- Artificial tumor microenvironment regulated by first hemorrhage for enhanced tumor targeting and then occlusion for synergistic bioactivation of hypoxia-sensitive platesomes.Acta pharmaceutica Sinica. B · 2022Article
- Cell membrane-camouflaged liposomes for tumor cell-selective glycans engineering and imaging in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis.Nature communications · 2021Article
- Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors.Molecules (Basel, Switzerland) · 2021Review
- Vascular disrupting agent induced aggregation of gold nanoparticles for photothermally enhanced tumor vascular disruption.Science advances · 2020Article
- Advances in nanomedicine for cancer starvation therapy.Theranostics · 2019Review
- Solid Tumor Therapy Using a Cannon and Pawn Combination Strategy.Theranostics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the pursuit of effective treatments for cancer, an emerging strategy is "active targeting", where nanoparticles are decorated with targeting ligands able to recognize and bind specific receptors overexpressed by tumor cells or tumor vasculature so that a greater fraction of the administered drugs are selectively trafficked to tumor sites. However, the implementation of this strategy has faced a major obstacle. The interpatient, inter- and intra-tumoral heterogeneity in receptor expression can pose challenges for the design of clinical trials and result in the paucity of targetable receptors within a tumor, which limits the effectiveness of "active targeting" strategy in cancer treatment. Here we report a cooperative drug delivery platform that overcomes the heterogeneity barrier unique to solid tumors. The cooperative platform comprises a coagulation-inducing agent and coagulation-targeted polymeric nanoparticles. As a typical small-molecule vascular disrupting agent (VDA), DMXAA can create a unique artificial coagulation environment with additional binding sites in a solid tumor by locally activating a coagulation cascade. Coagulation-targeted cisplatin-loaded nanoparticles, which are surface-decorated with a substrate of activated blood coagulation factor XIII, can selectively accumulate in the solid tumor by homing to the VDA-induced artificial coagulation environment through transglutamination.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.